SCHEMBL4189346

SCHEMBL4189346

CCC(=O)NC(C)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 1/20 0.50
FAAH O00519 3/20 0.49
MME P08473 2/20 0.48
ACE P12821 1/20 0.48
CPA1 P15085 1/20 0.48
ACE2 Q9BYF1 1/20 0.48
CYP2C9 P11712 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.46
TSHR P16473 1/20 0.46
SLC6A5 Q9Y345 1/20 0.46
LTA4H P09960 2/20 0.40
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10076082 1.00 ALDH1A1 (0.50) ALDH1A1MAPTFAAHMMEACE
SCHEMBL3159946 1.00 ALDH1A1 (0.50) ALDH1A1MAPTFAAHMMEACE
SCHEMBL11429905 0.91 MME (0.52) ALDH1A1MAPTFAAHMMEACE
SCHEMBL16199258 0.91 MME (0.52) ALDH1A1MAPTFAAHMMEACE
SCHEMBL6624097 0.89 CYP2C9 (0.45) ALDH1A1MAPTFAAHMMEACE
SCHEMBL6624100 0.89 CYP2C9 (0.45) ALDH1A1MAPTFAAHMMEACE
SCHEMBL23894144 0.85 PSMB5 (0.53) ALDH1A1MAPTFAAHMMEACE
SCHEMBL28310183 0.82 MME (0.47) ALDH1A1MAPTFAAHMMEACE
SCHEMBL28310182 0.82 MME (0.47) ALDH1A1MAPTFAAHMMEACE
SCHEMBL2269347 0.81 FAAH (0.59) ALDH1A1MAPTFAAHMMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186853-A1 COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J 2009-07-23 US claimed
EP-1865953-A4 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J (US) 2008-04-30 EP claimed
EP-1865953-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF Yu, Ruey J., Dr. (US) 2007-12-19 EP claimed
WO-2006101940-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU, RUEY, J. (US) 2006-09-28 WO claimed
US-20060211754-A1 Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof YU RUEY J 2006-09-21 US claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 US claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 WO claimed
CN-122037184-A Polyamide acid solution, preparation method thereof and polyimide film 中国石油天然气股份有限公司 2026-05-15 CN disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
CN-113874080-B IL-17A modulators and uses thereof 戴斯阿尔法公司 2024-09-27 CN disclosed
EP-4386090-A1 METHOD FOR DETERMINING AND IMPROVING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2024-06-19 EP disclosed
CN-117624207-A Glucose-sensitive albumin binding derivatives 诺和诺德股份有限公司 2024-03-01 CN disclosed
CN-111315751-B Glucose-sensitive albumin binding derivatives 诺和诺德股份有限公司 2023-12-12 CN disclosed
US-20020177599-A1 Pharmaceutically active compounds PFIZER INC. 2002-11-28 US disclosed
EP-1092719-A2 Imidazo[5,1-f][1,2,4]triazine derivatives Pfizer Limited (GB) 2001-04-18 EP disclosed
WO-1997026246-A1 SUBSTITUTED HISTIDINE INHIBITORS OF PROTEIN FARNESYLTRANSFERASE WARNER-LAMBERT COMPANY (US) 1997-07-24 WO disclosed
US-5466858-A Ruthenium catalyst, high selectivity with a carboxylic acid UBE INDUSTRIES, LTD. (JP) 1995-11-14 US disclosed
EP-0013261-B1 GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1982-12-01 EP disclosed
US-4299842-A TREATMENT OF RESPIRATORY SYSTEM DISORDERS, NUCOLYTIC AGENTS CAVAZZA CLAUDIO 1981-11-10 US disclosed
EP-0013261-A1 Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1980-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177599-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A ALDH1A1 403/4885MAPT 4711/4885FAAH 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.